Safety and Efficacy Study of VIS649 for IgA Nephropathy
Public ClinicalTrials.gov record NCT04287985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy
Study identification
- NCT ID
- NCT04287985
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Interventions
- Dose-Placebo Drug
- High Dose-VIS649 Drug
- Low Dose-VIS649 Drug
- Medium Dose-VIS649 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 19, 2020
- Primary completion
- May 18, 2023
- Completion
- Jun 17, 2023
- Last update posted
- Apr 23, 2026
2020 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Visterra Investigational Site | Birmingham | Alabama | 35294 | — |
| Visterra Investigational Site | Los Angeles | California | 90027 | — |
| Visterra Investigational Site | Oxnard | California | 93036 | — |
| Visterra Investigational Site | Palo Alto | California | 94305 | — |
| Visterra Investigational Site | Stanford | California | 94305 | — |
| Visterra Investigational Site | Denver | Colorado | 80230 | — |
| Visterra Investigational Site | Lawrenceville | Georgia | 30046 | — |
| Visterra Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| Visterra Investigational Site | New Orleans | Louisiana | 70121 | — |
| Visterra Investigational Site | Baltimore | Maryland | 21201 | — |
| Visterra Investigational Site | Tupelo | Mississippi | 38801 | — |
| Visterra Investigational Site | New York | New York | 10016 | — |
| Visterra Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| Visterra Investigational Site | Columbus | Ohio | 43210 | — |
| Visterra Investigational Site | Bethlehem | Pennsylvania | 18017 | — |
| Visterra Investigational Site | Houston | Texas | 77030 | — |
| Visterra Investigational Site | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04287985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04287985 live on ClinicalTrials.gov.